CIK 0001812364 · Large accelerated filer
Relay Therapeutics, Inc.
Sign in to watch- Ticker
- RLAY
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-370-8837
- Business address
- 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Open-market sale See remarks sold 753 shares at $18.62 ($14,021)
- 4 Open-market sale President, R&D sold 2,252 shares at $18.62 ($41,932)
- 4 Open-market sale Chief Financial Officer sold 1,469 shares at $18.62 ($27,353)
- 4 Planned sale President and CEO sold 48,199 shares at $18.10 ($872,402)
- 4 Planned sale Chief Financial Officer sold 17,717 shares at an average $18.59 ($329,322)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale President, R&D sold 8,530 shares at $18.97 ($161,814)
- 4 Planned sale Chief Financial Officer sold 17,717 shares at $18.94 ($335,560)
- 4 Planned sale President and CEO sold 48,199 shares at $18.94 ($912,889)
- 4 Planned sale See remarks sold 4,508 shares at $20.03 ($90,295)
- 4 Open-market sale 10% owner sold 6,000,000 shares at $19.40 ($116,400,000)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale President and CEO sold 48,199 shares at $20.33 ($979,886)
- 4 Planned sale Chief Financial Officer sold 17,717 shares at $19.74 ($349,734)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
Page 1 of 28 · 556 filings